Allegations that St. Jude Medical Inc.'s (NYSE: STJ) implantable heart devices have lax cybersecurity – leaving the devices vulnerable to attacks – are "false and misleading," the company said. Analysts have sided with St. Jude on the issue, for the most part, advising that the stock's short-term sell off based on the Muddy Waters Capital LLC (MW) report was unwarranted.

Ekso Bionics Holdings Inc. is evaluating the clinical value of its robotic exoskeleton for spinal cord injury (SCI) patients, reporting the first enrollement in its Walking Improvement for SCI with Exoskeletons (WISE) trial. Thomas Looby, president and CEO, said this is Ekso's first company-sponsored trial.

The first critical limb ischemia (CLI) patients have been enrolled in an FDA trial, under an investigational new drug (IND) application, for the Bullfrog micro-infusion device from Mercator Medsystems Inc.